All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$186 | -$175 | -$157 | -$124 | -$96 | -$74 |
| Non-Operating | ||||||
| Net Interest Expense | -$5 | -$5 | -$4 | -$2 | $0 | $0 |
| Income Tax Expense | -$3 | -$2 | $2 | $1 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$394 | -$288 | -$155 | -$118 | -$92 | -$72 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Basic) | -$3.61 | -$3.08 | -$2.30 | -$2.32 | -$2.16 | -$1.79 |
| EPS (Diluted) | -$4.62 | -$3.08 | -$2.30 | -$2.32 | -$2.16 | -$1.79 |
| Shares Outstanding | 135.0M | 93.5M | 67.5M | 51.0M | 42.4M | 40.0M |
Compass Pathways (CMPS) financials: revenue, profit and margins
Compass Pathways (CMPS) generated about $0.00 in revenue and -$394 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Compass Pathways's (CMPS) revenue?+
Compass Pathways generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Compass Pathways profitable?+
Compass Pathways reported about -$394 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Peers
Medical Care Facilities · Pick stocks to compare with CMPS
Held by ETFs
CMPS is in 13 US ETFs. The largest of them, with CMPS's weight in each:
iShares Biotechnology ETFIBB0.10%of the fund
ARK Genomic Revolution ETFARKG3.25%of the fund
- APActivePassive International Equity ETFAPIE0.02%of the fund
SPDR S&P International Small Cap ETFGWX0.13%of the fund
ProShares Ultra Nasdaq BiotechnologyBIB0.06%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CMPS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.